ZKB/PUT/ELI LILLY & CO/670/0.01/27.01.25 | Market Closed - Swiss Exchange 08:50:00 14/06/2024 pm IST | ||
| 0.14 CHF | -6.67% |
|
| Current month | -39.13% | ||
| 1 month | -60.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 0.14 | -6.67% |
| 13/24/13 | 0.15 | -6.25% |
| 11/24/11 | 0.16 | -5.88% |
| 10/24/10 | 0.17 | -5.56% |
| 07/24/07 | 0.18 | -5.26% |
Delayed Quote Swiss Exchange
Last update June 14, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | ZKB |
| LLY2YZ | |
| ISIN | CH1305143625 |
| Date issued | 08/03/2024 |
| Strike | 670 $ |
| Maturity | 27/01/2025 (226 Days) |
| Parity | 100 : 1 |
| Emission price | 0.42 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.48 CHF |
|---|---|
| Lowest since issue | 0.14 CHF |
| Spread | 0.01 CHF |
| Spread % | 7.14% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
- Stock Market
- Warrants
- LLY2YZ Warrant
